CLOs on the Move

CARsgen

www.carsgen.com

 
CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.carsgen.com
  • 6575 West Loop South Suite 455
    Bellaire, TX USA 77401
  • Phone: 346.293.9392

Executives

Name Title Contact Details
Sylvie Peltier
 Senior Vice President of Global Regulatory Affairs Profile

Similar Companies

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease

Cellares

Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.

ECHO

Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

AscidianTherapeutics